A database of FDA approved therapeutic peptides and proteins
Details of Th1203 which contains 1 entries. |
Entry 1 | |
(1) Primary information | |
---|---|
ID | 1812 |
ThPP ID | Th1203 |
Therapeutic Peptide/Protein Name | Peginterferon beta-1a |
Sequence | NA view full sequnce in fasta |
Functional Classification | Ia |
Molecular Weight | 20000 |
Chemical Formula | NA |
Isoelectric Point | NA |
Hydrophobicity | NA |
Melting Point (℃) | NA |
Half Life | Approximately 78 hours |
Description | Peginterferon beta-1a is an interferon beta-1a to which a single, linear 20,000 dalton (Da) methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde molecule is covalently attached to the alpha amino group of the N-terminal amino acid residue. The interferon beta-1a portion is produced as a glycosylated protein using genetically-engineered Chinese hamster ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of the recombinant interferon beta-1a is identical to that of the human interferon beta counterpart. |
Indication/Disease | For the treatment of patients with relapsing forms of multiple sclerosis. |
Pharmacodynamics | There is no biochemical or physiologic effect known to relate directly to the clinical effect of PLEGRIDY. |
Mechanism of Action | The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown. |
Toxicity | NA |
Metabolism | Clearance mechanisms for PLEGRIDY include catabolism and excretion. The major pathway of elimination is renal. |
Absorption | The mean Cmax was 280 pg/mL, and the AUC over the 14 day dosing interval was 34.8 ng.hr/mL. |
Volume of Distribution | The estimated volume of distribution was 481 liters |
Clearance | The mean steady state clearance of PLEGRIDY is approximately 4.1 L/hr |
Categories | NA |
Patents Number | NA |
Date of Issue | NA |
Date of Expiry | NA |
Drug Interaction | Theophylline, Zidovudine |
Target | |
Information of corresponding available drug in the market | |
Brand Name | Plegridy |
Company | Biogen Canada Inc |
Brand Discription | The interferon beta-1a portion of PLEGRIDY is produced as a glycosylated protein using genetically-engineered Chinese hamster ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of the recombinant interferon beta-1a is identical to that of the human interferon beta counterpart. |
Prescribed for | PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. |
Chemical Name | Methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde |
Formulation | Prefilled glass syringe containing 0.5 mL of a sterile solution in water for injection of 63, 94, or 125 micrograms of peginterferon beta-1a |
Physcial Appearance | Sterile Solution |
Route of Administration | Subcutaneous |
Recommended Dosage | The recommended dosage of PLEGRIDY is 125 micrograms injected subcutaneously every 14 days. |
Contraindication | PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of the formulation |
Side Effects | Hepatic Injury; Depression and Suicide; Seizures; Anaphylaxis and Other Allergic Reactions; Injection Site Reactions; Congestive Heart Failure; Decreased Peripheral Blood Counts; Thrombotic Microangiopathy; Autoimmune Disorders. |
Useful Link | http://www.rxlist.com/plegridy-drug/side-effects-interactions.htm |
PubMed ID | 27835061, 27314959, 26039748, 25941954, 25846320, 25666445, 25432952, 24794721, 24556656 |
3-D Structure | N.A. |